Symbols / SNGX Stock $1.39 +1.46% Soligenix, Inc.

Healthcare • Biotechnology • United States • NCM
SNGX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Christopher J. Schaber Ph.D.
Exch · Country NCM · United States
Market Cap 14.33M
Enterprise Value 6.75M
Income -11.08M
Sales —
FCF (ttm) -6.31M
Book/sh 0.53
Cash/sh 0.77
Employees 13
Insider 10d —
IPO Apr 04, 1994
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.64
PEG —
P/S —
P/B 2.65
P/C —
EV/EBITDA -0.57
EV/Sales —
Quick Ratio 2.15
Current Ratio 2.39
Debt/Eq 6.77
LT Debt/Eq —
EPS (ttm) -2.14
EPS next Y -0.85
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-07
Earnings (prior) 2025-11-07
ROA -81.35%
ROE -235.50%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 10.31M
Shs Float 9.76M
Insider Own 0.15%
Instit Own 9.49%
Short Float 7.86%
Short Ratio 2.46
Short Interest 809.14K
52W High 6.23
vs 52W High -77.69%
52W Low 1.00
vs 52W Low 39.00%
Beta 1.94
Impl. Vol. —
Rel Volume 0.26
Avg Volume 238.58K
Volume 61.08K
Target (mean) $15.00
Tgt Median $15.00
Tgt Low $10.00
Tgt High $20.00
# Analysts 2
Recom None
Prev Close $1.37
Price $1.39
Change 1.46%
About

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.00
Mean price target
2. Current target
$1.39
Latest analyst target
3. DCF / Fair value
$-11.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.39
Low
$10.00
High
$20.00
Mean
$15.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-07-16 main Alliance Global Partners Buy → Buy $6
News
RSS: Latest SNGX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-02 SCHABER CHRISTOPHER J Chief Executive Officer — 15,132 $1.32 $20,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
0.25
Operating Revenue
0.00
0.00
0.00
-100.00%
0.25
Cost Of Revenue
0.00
-100.00%
0.12
-83.91%
0.74
+34.72%
0.55
Reconciled Cost Of Revenue
0.00
-100.00%
0.12
-83.91%
0.74
+34.72%
0.55
Gross Profit
0.00
+100.00%
-0.12
+83.91%
-0.74
-146.67%
-0.30
Operating Expense
11.85
+26.75%
9.35
+34.82%
6.93
-49.79%
13.81
Research And Development
7.49
+43.31%
5.22
+57.68%
3.31
-58.30%
7.94
Selling General And Administration
4.36
+3.41%
4.22
-5.95%
4.48
-33.03%
6.69
General And Administrative Expense
4.36
+3.41%
4.22
-5.95%
4.48
-33.03%
6.69
Other Gand A
4.36
+3.41%
4.22
-5.95%
4.48
-33.03%
6.69
Other Operating Expenses
—
-0.09
+89.12%
-0.86
-3.77%
-0.83
Total Expenses
11.85
+25.15%
9.46
+23.34%
7.67
-46.54%
14.36
Operating Income
-11.85
-25.15%
-9.46
-23.34%
-7.67
+45.60%
-14.11
Total Operating Income As Reported
-11.85
-25.49%
-9.44
-22.62%
-7.70
+45.94%
-14.24
EBITDA
-11.84
-25.19%
-9.46
-23.37%
-7.67
+45.64%
-14.11
Normalized EBITDA
-11.83
-17.90%
-10.03
-34.89%
-7.44
+47.15%
-14.08
Reconciled Depreciation
0.00
-44.55%
0.01
-11.29%
0.01
-73.32%
0.02
EBIT
-11.85
-25.15%
-9.46
-23.34%
-7.67
+45.69%
-14.13
Total Unusual Items
-0.01
-102.05%
0.58
+351.79%
-0.23
-647.88%
-0.03
Total Unusual Items Excluding Goodwill
-0.01
-102.05%
0.58
+351.79%
-0.23
-647.88%
-0.03
Special Income Charges
0.00
-100.00%
0.31
+214.55%
-0.27
0.00
Other Special Charges
—
-0.31
-214.55%
0.27
—
Net Income
-11.08
-34.04%
-8.27
-34.62%
-6.14
+55.50%
-13.80
Pretax Income
-11.59
-33.56%
-8.68
-9.70%
-7.91
+47.11%
-14.95
Net Non Operating Interest Income Expense
0.27
+26.26%
0.21
+535.54%
-0.05
+94.03%
-0.82
Interest Expense Non Operating
—
-0.21
-535.54%
0.05
-94.03%
0.82
Net Interest Income
0.27
+26.26%
0.21
+535.54%
-0.05
+94.03%
-0.82
Interest Expense
—
-0.21
-535.54%
0.05
-94.03%
0.82
Other Income Expense
-0.01
-102.03%
0.58
+410.57%
-0.19
-652.18%
-0.02
Other Non Operating Income Expenses
0.00
+190.70%
0.00
-99.90%
0.04
+629.99%
0.01
Gain On Sale Of Security
-0.01
-104.50%
0.26
+489.29%
0.04
+245.83%
-0.03
Tax Provision
-0.51
-23.83%
-0.41
+76.86%
-1.77
-53.07%
-1.15
Tax Rate For Calcs
0.00
-6.38%
0.00
-79.02%
0.00
+190.91%
0.00
Tax Effect Of Unusual Items
-0.00
-101.92%
0.03
+152.83%
-0.05
-2075.66%
-0.00
Net Income Including Noncontrolling Interests
-11.08
-34.04%
-8.27
-34.62%
-6.14
+55.50%
-13.80
Net Income From Continuing Operation Net Minority Interest
-11.08
-34.04%
-8.27
-34.62%
-6.14
+55.50%
-13.80
Net Income From Continuing And Discontinued Operation
-11.08
-34.04%
-8.27
-34.62%
-6.14
+55.50%
-13.80
Net Income Continuous Operations
-11.08
-34.04%
-8.27
-34.62%
-6.14
+55.50%
-13.80
Normalized Income
-11.07
-25.57%
-8.81
-47.81%
-5.96
+56.69%
-13.77
Net Income Common Stockholders
-11.08
-34.04%
-8.27
-34.62%
-6.14
+55.50%
-13.80
Diluted EPS
-2.14
+57.03%
-4.98
+60.66%
-12.66
+83.55%
-76.96
Basic EPS
-2.14
+57.03%
-4.98
+60.66%
-12.66
+83.55%
-76.96
Basic Average Shares
5.19
+212.50%
1.66
+242.36%
0.48
+170.25%
0.18
Diluted Average Shares
5.19
+212.50%
1.66
+242.36%
0.48
+170.25%
0.18
Diluted NI Availto Com Stockholders
-11.08
-34.04%
-8.27
-34.62%
-6.14
+55.50%
-13.80
Total Other Finance Cost
-0.27
-26.26%
-0.21
-535.54%
0.05
—
Line Item Trend 2023-12-31
Total Assets
9.80
Current Assets
9.51
Cash Cash Equivalents And Short Term Investments
8.45
Cash And Cash Equivalents
8.45
Receivables
0.20
Accounts Receivable
0.00
Other Receivables
0.20
Prepaid Assets
—
Current Deferred Assets
0.00
Other Current Assets
0.87
Total Non Current Assets
0.29
Net PPE
0.24
Gross PPE
0.24
Accumulated Depreciation
-0.12
Properties
0.00
Buildings And Improvements
0.23
Machinery Furniture Equipment
0.01
Other Properties
—
Non Current Accounts Receivable
0.03
Non Current Deferred Assets
0.00
Non Current Prepaid Assets
0.02
Other Non Current Assets
—
Total Liabilities Net Minority Interest
7.27
Current Liabilities
6.15
Payables And Accrued Expenses
3.53
Payables
1.11
Accounts Payable
1.11
Current Accrued Expenses
2.42
Pensionand Other Post Retirement Benefit Plans Current
0.25
Current Debt And Capital Lease Obligation
2.37
Current Debt
2.25
Other Current Borrowings
2.25
Current Capital Lease Obligation
0.12
Total Non Current Liabilities Net Minority Interest
1.12
Long Term Debt And Capital Lease Obligation
1.12
Long Term Debt
1.01
Long Term Capital Lease Obligation
0.11
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
2.52
Common Stock Equity
2.52
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.65
Ordinary Shares Number
0.65
Treasury Shares Number
0.00
Additional Paid In Capital
228.20
Retained Earnings
-225.70
Gains Losses Not Affecting Retained Earnings
0.02
Other Equity Adjustments
0.02
Total Equity Gross Minority Interest
2.52
Total Capitalization
3.53
Working Capital
3.36
Invested Capital
5.78
Total Debt
3.49
Capital Lease Obligations
0.23
Net Tangible Assets
2.52
Tangible Book Value
2.52
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.27
-22.17%
-8.40
+2.33%
-8.60
+31.98%
-12.65
Cash Flow From Continuing Operating Activities
-10.27
-22.17%
-8.40
+2.33%
-8.60
+31.98%
-12.65
Net Income From Continuing Operations
-11.08
-34.04%
-8.27
-34.62%
-6.14
+55.50%
-13.80
Depreciation Amortization Depletion
0.00
-44.55%
0.01
-11.29%
0.01
-73.32%
0.02
Depreciation And Amortization
0.00
-44.55%
0.01
-11.29%
0.01
-73.32%
0.02
Other Non Cash Items
0.19
+39.90%
0.14
-44.59%
0.25
-32.65%
0.37
Stock Based Compensation
0.59
+78.16%
0.33
-10.90%
0.37
+11.04%
0.33
Operating Gains Losses
—
—
0.39
—
Gain Loss On Investment Securities
—
—
-0.04
—
Unrealized Gain Loss On Investment Securities
0.00
+100.00%
-0.26
-505.89%
-0.04
—
Change In Working Capital
0.03
+109.13%
-0.35
+89.86%
-3.44
-908.61%
0.43
Change In Receivables
0.00
-100.00%
0.22
+548.82%
0.03
-65.11%
0.10
Changes In Account Receivables
—
—
—
0.02
Change In Prepaid Assets
0.01
+127.91%
-0.04
+93.37%
-0.59
-6907.05%
0.01
Change In Payables And Accrued Expense
0.14
+133.19%
-0.41
+85.30%
-2.77
-743.73%
0.43
Change In Accrued Expense
0.15
+77.77%
0.09
+199.71%
-0.09
-353.52%
0.03
Change In Payable
-0.02
+96.65%
-0.49
+81.65%
-2.69
-776.94%
0.40
Change In Account Payable
-0.02
+96.65%
-0.49
+81.65%
-2.69
-776.94%
0.40
Change In Other Working Capital
—
—
—
0.03
Change In Other Current Liabilities
-0.11
+6.11%
-0.12
-11.76%
-0.11
+1.96%
-0.11
Investing Cash Flow
-0.01
0.00
0.00
+100.00%
-0.01
Cash Flow From Continuing Investing Activities
-0.01
0.00
0.00
+100.00%
-0.01
Net PPE Purchase And Sale
-0.01
0.00
0.00
+100.00%
-0.01
Purchase Of PPE
-0.01
0.00
0.00
+100.00%
-0.01
Capital Expenditure
-0.01
—
—
-0.01
Financing Cash Flow
10.39
+33.84%
7.76
+111.88%
3.66
+4668.89%
0.08
Cash Flow From Continuing Financing Activities
10.39
+33.84%
7.76
+111.88%
3.66
+4668.89%
0.08
Net Issuance Payments Of Debt
-1.37
0.00%
-1.37
+80.39%
-7.00
0.00
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-1.37
0.00%
-1.37
+80.39%
-7.00
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-1.37
0.00%
-1.37
+80.39%
-7.00
0.00
Net Long Term Debt Issuance
-1.37
0.00%
-1.37
+80.39%
-7.00
0.00
Net Common Stock Issuance
12.16
+109.27%
5.81
-49.83%
11.59
+14502.01%
0.08
Proceeds From Stock Option Exercised
0.31
-93.14%
4.45
+134794.57%
0.00
0.00
Net Other Financing Charges
-0.71
+37.22%
-1.13
-21.69%
-0.93
-36499.76%
-0.00
Changes In Cash
0.12
+118.18%
-0.64
+87.02%
-4.94
+60.74%
-12.59
Effect Of Exchange Rate Changes
0.00
-100.00%
0.01
-45.17%
0.03
+127.42%
-0.10
Beginning Cash Position
7.82
-7.42%
8.45
-36.78%
13.36
-48.70%
26.04
End Cash Position
7.94
+1.49%
7.82
-7.42%
8.45
-36.78%
13.36
Free Cash Flow
-10.27
-22.24%
-8.40
+2.33%
-8.60
+32.05%
-12.66
Interest Paid Supplemental Data
0.04
-84.61%
0.23
-58.75%
0.55
-35.61%
0.86
Income Tax Paid Supplemental Data
0.12
+189.73%
0.04
+103.39%
0.02
+29.22%
0.02
Common Stock Issuance
12.16
+109.27%
5.81
-49.83%
11.59
+14502.01%
0.08
Issuance Of Capital Stock
12.16
+109.27%
5.81
-49.83%
11.59
+14502.01%
0.08
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category